Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.Haematologica|February 2, 2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Mark Hertzberg, Maher K Gandhi, Judith Trotman, et al.Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.Journal of Thrombosis and Haemostasis : JTH|September 15, 2022
Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patientsEmmanuel J Favaloro, Joanne Clifford, Emma Leitinger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.Pageof 2